Drug royalty ruling leaves scars on biotech and its sibling company
The dispute centered on how to use royalties from the GlaxoSmithKline blockbuster COPD and asthma drug Trelegy.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Ron Leuty Source Type: news
More News: American Health | Asthma | Biotechnology | Chronic Obstructive Pulmonary | Health Management